Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on 4SC AG. We currently have 7 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
First patient enrolled in pivotal RESMAIN study
19 Dec 16
4SC has announced the enrolment of the first patient in its RESMAIN study. This is a pivotal study to evaluate resminostat (RES), an epigenetic cancer drug for maintenance treatment (MAIN) in patients with advanced-stage cutaneous T-cell lymphoma (CTCL). We expect early data to be reported in 2019. We increase our rNPV to €120m from €117m as we have raised the probability of the CTCL programme in Europe to 30% (from 20%) following the initiation of the trial.
Positive detailed analysis of Phase II trial data
06 Oct 16
4SC has announced positive Phase II results from a more detailed analysis of the HCC Yakult Phase II trial data, which we believe could lead to further clinical development. It has also recently announced the sale of its immunology portfolio (Vidofludimus and a cytokine inhibitor), which further streamlines the company’s focus further on its core business of epigenetics while retaining potential upside (via milestones and royalties). We increase our rNPV to €117m from €110m to reflect the increase in potential of resminostat development in Japan.
Core focus on track despite disappointing results
13 Jun 16
4SC has announced that its partner Yakult Honsha did not reach the primary endpoint in its Asian liver cancer trial with all-comer patients. As a result, it will not be progressing resminostat to a pivotal study. These results do not affect 4SC’s core focus on the launch of its pivotal EU Phase II resminostat study in CTCL and progression of its earlier pipeline. A positive partnership with Link Health (4SC-205) and data at ASCO (4SC-202) underline this. Removal of the Japan HCC contribution reduces our rNPV to €104m (vs €145m).
Increased focus on core business
19 May 16
4SC’s Q1 results highlight an increased focus on its core business of epigenetic research and commercialisation, resulting from the sale of the operational assets (for €650k in proceeds) of its discovery and collaborative segment, 4SC Discovery. 2016 is an important year for 4SC with expected newsflow from its clinical pipeline including the launch of its potentially pivotal EU Phase II study with resminostat in Cutaneous T-cell lymphoma (CTCL) and expected Phase II Japanese trial data in HCC and NSCLC (from partner Yakult).
Important progression of clinical pipeline in 2016
01 Apr 16
2016 is an important year for 4SC as it will launch its potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL. In addition, we expect partner Yakult to report Phase II Japanese trial data in HCC and NSCLC. Alongside its primary focus on resminostat for CTCL, 4SC is actively pursuing partnerships for its earlier stage assets, 4SC-202 and 4SC-205, which would enable both candidates to move into Phase II. We maintain our rNPV at €143m, with near-term potential catalysts.
Pioneering epigenetics in cancer
21 Mar 16
The 4SC oncology strategy is primarily driven by epigenetics, a distinct and effective mechanism against many cancers. A potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL is due to start in H116, while partner Yakult should reveal Phase II Japanese trial data in HCC and NSCLC in 2016. Financings and/or collaborations may allow 4SC-202 and 4SC-205 to move into Phase II. We have made adjustments to our model to include a specific value for 4SC-202. Our rNPV rises slightly to €143m (€7.55 per share), with near-term potential upside on initiation of the Phase II CTCL study.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
11 Jan 17
Joules Group (JOU): Strong festive trading (BUY) | Shoe Zone (SHOE): Tough FY16 could be just the beginning (HOLD) | H&T (HAT): Alternative lender emerging (BUY) | Omega Diagnostics* (ODX): ISO accreditation received for Pune, India (CORP) | Redcentric* (RCN): Interims – restoring forecasts (CORP)
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.